Hemostemix Stock Today
| HMTXF Stock | USD 0.06 0 5.36% |
PerformanceWeakest
| Odds Of DistressRisky
|
Hemostemix is trading at 0.0629 as of the 26th of December 2025. This is a 5.36 percent increase since the beginning of the trading day. The stock's lowest day price was 0.0629. Hemostemix has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 27th of September 2025 and ending today, the 26th of December 2025. Click here to learn more.
Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. The company has 75.74 M outstanding shares. More on Hemostemix
Moving against Hemostemix OTC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Hemostemix OTC Stock Highlights
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Hemostemix [HMTXF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.96 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hemostemix's market, we take the total number of its shares issued and multiply it by Hemostemix's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Hemostemix classifies itself under Biotechnology sector and is part of Health Care industry. The entity has 75.74 M outstanding shares.
Hemostemix has accumulated about 649.32 K in cash with (3.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Check Hemostemix Probability Of Bankruptcy
Ownership AllocationHemostemix has a total of 75.74 Million outstanding shares. Hemostemix retains 12.4 (percent) of its outstanding shares held by insiders and 0.0 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Hemostemix Ownership Details
Hemostemix Risk Profiles
| Mean Deviation | 2.42 | |||
| Standard Deviation | 4.18 | |||
| Variance | 17.49 | |||
| Risk Adjusted Performance | (0.03) |
Hemostemix Stock Against Markets
Picking the right benchmark for Hemostemix otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Hemostemix otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Hemostemix is critical whether you are bullish or bearish towards Hemostemix at a given time. Please also check how Hemostemix's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Hemostemix without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
Hemostemix Corporate Management
Elected by the shareholders, the Hemostemix's board of directors comprises two types of representatives: Hemostemix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hemostemix. The board's role is to monitor Hemostemix's management team and ensure that shareholders' interests are well served. Hemostemix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hemostemix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA | President, CoFounder | Profile | |
| MD Sr | Chief Officer | Profile | |
| Thomas CA | Pres Inc | Profile | |
| Peter Pavlin | VP Operations | Profile | |
| Cameron Cole | Head Relations | Profile | |
| Christina CPA | Interim Officer | Profile |
Other Information on Investing in Hemostemix OTC Stock
Hemostemix financial ratios help investors to determine whether Hemostemix OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hemostemix with respect to the benefits of owning Hemostemix security.